Chronic liver injury induced by drugs: A systematic review

Liver International

Volumn 35, Issue 11, 2015, Pages 2343-2353

  Stine, Jonathan G ^a   Chalasani, Naga ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmune hepatitis; Cirrhosis; Drug induced liver injury; Hepatology; Liver disease; Liver transplantation

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AUTOANTIBODY; AZITHROMYCIN; CARBAMAZEPINE; CHLORPROMAZINE; CORTICOSTEROID; COTRIMOXAZOLE; DIDANOSINE; DILTIAZEM; ESTROGEN; FENOFIBRATE; FLUOROURACIL; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERFERON; LIVER ENZYME; MACROLIDE; METHOTREXATE; METHYLDOPA; MINOCYCLINE; NITROFURANTOIN; NONSTEROID ANTIINFLAMMATORY AGENT; STAVUDINE; SULFONAMIDE; TAMOXIFEN; TERBINAFINE; TETRACYCLINE; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VALPROIC ACID; ANTIINFECTIVE AGENT;

ACUTE DISEASE; ANTIBIOTIC THERAPY; ARTICLE; AUTOIMMUNITY; CHOLESTATIC LIVER INJURY; CHRONIC DISEASE; CHRONIC LIVER DISEASE; CHRONIC LIVER INJURY; CHRONICITY; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INDUCED FATTY LIVER; DRUG INDUCED HEPATIC STEATOSIS; DRUG INDUCED NODULAR REGENERATIVE HYPERPLASIA; DRUG INDUCED PELIOSIS HEPATITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CIRRHOSIS; LIVER TOXICITY; PELIOSIS HEPATITIS; PERSONALIZED MEDICINE; PHARMACOGENOMICS; TOXIC HEPATITIS; TREATMENT DURATION; CHEMICALLY INDUCED; CHOLESTASIS; CLASSIFICATION; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; LIVER;

ANTI-BACTERIAL AGENTS; CHOLESTASIS; DRUG-INDUCED LIVER INJURY; HUMANS; LIVER;

EID: 84945490369     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12958     Document Type: Article

References (146)

1. Bjornsson E, Jerlstad P, Bergqvist A, Olsson R. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol 2005; 40: 1095-101.
2. Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-34, 34.e1-4.
3. Stine JG, Lewis JH. Drug-induced liver injury: a summary of recent advances. Expert Opin Drug Metab Toxicol 2011; 7: 875-90.
4. Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-21.
5. Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol 2014; 109: 950-66; quiz 67.
6. Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN Prospective Study. Gastroenterology 2015; 148: 1340-52.e7.
7. Andrade RJ, Lucena MI, Kaplowitz N, et al. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology 2006; 44: 1581-8.
8. Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011; 89: 806-15.
9. Bjornsson E, Talwalkar J, Treeprasertsuk S, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 2010; 51: 2040-8.
10. Suzuki A, Brunt EM, Kleiner DE, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology 2011; 54: 931-9.
11. O'Brien CB, Shields DS, Saul SH, Reddy KR. Drug-induced vanishing bile duct syndrome: response to ursodiol. Am J Gastroenterol 1996; 91: 1456-7.
12. Desmet VJ. Vanishing bile duct syndrome in drug-induced liver disease. J Hepatol 1997; 26(Suppl. 1): 31-5.
13. Pusl T, Beuers U. Ursodeoxycholic acid treatment of vanishing bile duct syndromes. World J Gastroenterol 2006; 12: 3487-95.
14. Reau NS, Jensen DM. Vanishing bile duct syndrome. Clin Liver Dis 2008; 12: 203-17, x.
15. Amacher DE, Chalasani N. Drug-induced hepatic steatosis. Semin Liver Dis 2014; 34: 205-14.
16. Nadell J, Kosek J. Peliosis hepatis. Twelve cases associated with oral androgen therapy. Arch Pathol Lab Med 1977; 101: 405-10.
17. Olsson R, Wiholm BE, Sand C, et al. Liver damage from flucloxacillin, cloxacillin and dicloxacillin. J Hepatol 1992; 15: 154-61.
18. Bjornsson E, Davidsdottir L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. J Hepatol 2009; 50: 511-17.
19. Delemos AS, Foureau DM, Jacobs C, et al. Drug-induced liver injury with autoimmune features. Semin Liver Dis 2014; 34: 194-204.
20. Ghabril M, Bonkovsky HL, Kum C, et al. Liver injury from tumor necrosis factor-alpha antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol 2013; 11: 558-64 e3.
21. Reuben A, Koch DG, Lee WM. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010; 52: 2065-76.
22. Devarbhavi H, Dierkhising R, Kremers WK, et al. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol 2010; 105: 2396-404.
23. Aouam K, Ben Romdhane F, Loussaief C, et al. Hypersensitivity syndrome induced by anticonvulsants: possible cross-reactivity between carbamazepine and lamotrigine. J Clin Pharmacol 2009; 49: 1488-91.
24. Zimmerman HJ. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. 2nd edn. Philadelphia: Lippincott-Williams & Wilkins, 1999.
25. Forbes GM, Jeffrey GP, Shilkin KB, Reed WD. Carbamazepine hepatotoxicity: another cause of the vanishing bile duct syndrome. Gastroenterology 1992; 102(4 Pt 1): 1385-8.
26. Roberts WC. Safety of fenofibrate-US and worldwide experience. Cardiology 1989; 76: 169-79.
27. Dumortier J, Slim R, Chevallier M, et al. Acute severe fibrosing hepatitis associated with ciprofibrate treatment. Gastroenterol Clin Biol 1999; 23: 1399-400.
28. Chatrenet P, Regimbeau C, Ramain JP, Penot J, Bruandet P. Chronic active cirrhogenic hepatitis induced by fenofibrate. Gastroenterol Clin Biol 1993; 17: 612-13.
29. Bernard PH, Lamouliatte H, Le Bail B, et al. Chronic active hepatitis associated with antinuclear antibodies induced by fenofibrate. Gastroenterol Clin Biol 1994; 18: 1048-9.
30. Parra JL, Reddy KR. Hepatotoxicity of hypolipidemic drugs. Clin Liver Dis 2003; 7: 415-33.
31. Couzigou P, Boutillier P, Boisseau C, et al. Drug-induced hepatitis due to fenofibrate. Therapie 1980; 35: 403.
32. Stine JG, Lewis JH. Hepatotoxicity of antibiotics: a review and update for the clinician. Clin Liver Dis 2013; 17: 609-42, ix.
33. Juricic D, Hrstic I, Radic D, et al. Vanishing bile duct syndrome associated with azithromycin in a 62-year-old man. Basic Clin Pharmacol Toxicol 2010; 106: 62-5.
34. Wallace RJ Jr, Brown BA, Griffith DE. Drug intolerance to high-dose clarithromycin among elderly patients. Diagn Microbiol Infect Dis 1993; 16: 215-21.
35. Sousa C, Correia J, Santos J, Silvestre F, Bernardo A. Cholestatic hepatitis probably induced by clarithromycin. Gastroenterol Clin Biol 1997; 21: 632-3.
36. Hilgers RD, Alberts DS, Standefer JC, et al. Phase II and pharmacokinetic study of high-dose methotrexate in the treatment of advanced gynecologic malignancy. A Southwest Oncology Group Trial. Gynecol Oncol 1984; 18: 62-70.
37. Gabriel S, Creagan E, O'Fallon WM, Jaquith J, Bunch T. Treatment of rheumatoid arthritis with higher dose intravenous methotrexate. J Rheumatol 1990; 17: 460-5.
38. Weinstein GD, Cox JW, Suringa DW, et al. Evaluation of possible chronic hepatotoxicity from methotrexate for psoriasis. Arch Dermatol 1970; 102: 613-18.
39. Nyfors A. Liver biopsies from psoriatics related to methotrexate therapy 3. Findings in post-methotrexate liver biopsies from 160 psoriatics. Acta Pathol Microbiol Scand A 1977; 85: 511-18.
40. Zachariae H, Kragballe K, Sogaard H. Methotrexate induced liver cirrhosis. Studies including serial liver biopsies during continued treatment. Br J Dermatol 1980; 102: 407-12.
41. Dawwas MF, Aithal GP. End-stage methotrexate-related liver disease is rare and associated with features of the metabolic syndrome. Aliment Pharmacol Ther 2014; 40: 938-48.
42. Kamen BA, Nylen PA, Camitta BM, Bertino JR. Methotrexate accumulation and folate depletion in cells as a possible mechanism of chronic toxicity to the drug. Br J Haematol 1981; 49: 355-60.
43. Van Ede AE, Laan RF, Rood MJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001; 44: 1515-24.
44. Kremer JM, Alarcon GS, Lightfoot RW Jr, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994; 37: 316-28.
45. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 762-84.
46. Podymow T, August P. Hypertension in pregnancy. Adv Chronic Kidney Dis 2007; 14: 178-90.
47. Goldstein GB, Lam KC, Mistilis SP. Drug-induced active chronic hepatitis. Am J Dig Dis 1973; 18: 177-84.
48. Toghill PJ, Smith PG, Benton P, Brown RC, Matthews HL. Methyldopa liver damage. Br Med J 1974; 3: 545-8.
49. Sotaniemi EA, Hokkanen OT, Ahokas JT, Pelkonen RO, Ahlqvist J. Hepatic injury and drug metabolism in patients with alpha-methyldopa-induced liver damage. Eur J Clin Pharmacol 1977; 12: 429-35.
50. Arranto AJ, Sotaniemi EA. Morphologic alterations in patients with alpha-methyldopa-induced liver damage after short- and long-term exposure. Scand J Gastroenterol 1981; 16: 853-63.
51. Beaugrand M, Gavillon C, Ferrier JP. [High levels of endoplasmic reticulum antibody titer in a case of alpha-methyldopa-induced chronic active hepatitis (author's transl)]. Gastroenterol Clin Biol 1980; 4: 219-21.
52. Lee WM, Denton WT. Chronic hepatitis and indolent cirrhosis due to methyldopa: the bottom of the iceberg? J S C Med Assoc 1989; 85: 75-9.
53. Seeverens H, De Bruin CD, Jordans JG. Myocarditis and methyldopa. Acta Med Scand 1982; 211: 233-5.
54. Arranto AJ, Sotaniemi EA. Histologic follow-up of alpha-methyldopa-induced liver injury. Scand J Gastroenterol 1981; 16: 865-72.
55. Gough A, Chapman S, Wagstaff K, Emery P, Elias E. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ 1996; 312: 169-72.
56. Knowles SR, Shapiro L, Shear NH. Serious adverse reactions induced by minocycline. Report of 13 patients and review of the literature. Arch Dermatol 1996; 132: 934-9.
57. Gleckman R, Alvarez S, Joubert DW. Drug therapy reviews: nitrofurantoin. Am J Hosp Pharm 1979; 36: 342-51.
58. Sharp JR, Ishak KG, Zimmerman HJ. Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. Ann Intern Med 1980; 92: 14-19.
59. Amit G, Cohen P, Ackerman Z. Nitrofurantoin-induced chronic active hepatitis. Isr Med Assoc J 2002; 4: 184-6.
60. Sippel PJ, Agger WA. Nitrofurantoin-induced granulomatous hepatitis. Urology 1981; 18: 177-8.
61. Strohscheer H, Wegener HH. [Nitrofurantoin-induced granulomatous hepatitis]. MMW Munch Med Wochenschr 1977; 119: 1535-6.
62. Lindberg J, Lindholm A, Iwarson S. Genetic factors in the development of chronic active hepatitis. Lancet 1977; 1: 67-8.
63. Selroos O, Edgren J. Lupus-like syndrome associated with pulmonary reaction to nitrofurantoin. Report of three cases. Acta Med Scand 1975; 197: 125-9.
64. Iwarson S, Lindberg J, Lundin P. Nitrofurantoin-induced chronic liver disease. Clinical course and outcome of five cases. Scand J Gastroenterol 1979; 14: 497-502.
65. Klemola H, Penttila O, Runeberg L, Tallqvist G. Anicteric liver damage during nitrofurantoin medication. Scand J Gastroenterol 1975; 10: 501-5.
66. Fagrell B, Strandberg I, Wengle B. A nitrofurantoin-induced disorder simulating chronic active hepatitis. A case report. Acta Med Scand 1976; 199: 237-9.
67. DRUGS. F D S C I S L C T C-L S.
68. Lewis JH. Clinical perspective: statins and the liver-harmful or helpful? Dig Dis Sci 2012; 57: 1754-63.
69. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006; 97: 52C-60C.
70. Clarke AT, Mills PR. Atorvastatin associated liver disease. Diges Liver Dis 2006; 38: 772-7.
71. Russo MW, Hoofnagle JH, Gu J, et al. Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology 2014; 60: 679-86.
72. Rzouq FS, Volk ML, Hatoum HH, et al. Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians. Am J Med Sci 2010; 340: 89-93.
73. Funatsu T, Kakuta H, Takasu T, et al. Experimental model of postprandial hypertriglyceridemia in sucrose-fed rats and the effectiveness of atorvastatin in the model. Metabolism 2003; 52: 609-15.
74. Pelli N, Setti M, Ceppa P, Toncini C, Indiveri F. Autoimmune hepatitis revealed by atorvastatin. Eur J Gastroenterol Hepatol 2003; 15: 921-4.
75. Alla V, Abraham J, Siddiqui J, et al. Autoimmune hepatitis triggered by statins. J Clin Gastroenterol 2006; 40: 757-61.
76. Van Heyningen C. Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe. Ann Clin Biochem 2005; 42(Pt 5): 402-4.
77. Wolters LM, Van Buuren HR. Rosuvastatin-associated hepatitis with autoimmune features. Eur J Gastroenterol Hepatol 2005; 17: 589-90.
78. Kasliwal R, Wilton LV, Cornelius V, Aurich-Barrera B, Shakir SA. Safety profile of rosuvastatin: results of a prescription-event monitoring study of 11 680 patients. Drug Saf 2007; 30: 157-70.
79. Punthakee Z, Scully LJ, Guindi MM, Ooi TC. Liver fibrosis attributed to lipid lowering medications: two cases. J Intern Med 2001; 250: 249-54.
80. Castiella A, Fernandez J, Zapata E. Autoimmune hepatitis after treatment with fluvastatin. Liver Int 2007; 27: 592.
81. McQueen MJ. Cholestatic jaundice associated with lovastatin (Mevacor) therapy. CMAJ 1990; 142: 841-2.
82. Azinge NO, Garrick GA. Stevens-Johnson syndrome (erythema multiforme) following ingestion of trimethoprim-sulfamethoxazole on two separate occasions in the same person: a case report. J Allergy Clin Immunol 1978; 62: 125-6.
83. Mainra RR, Card SE. Trimethoprim-sulfamethoxazole-associated hepatotoxicity - part of a hypersensitivity syndrome. Can J Clin Pharmacol 2003; 10: 175-8.
84. Espiritu CR, Kim TS, Levine RA. Granulomatous hepatitis associated with sulfadimethoxine hypersensitivity. JAMA 1967; 202: 985-8.
85. Yao F, Behling CA, Saab S, et al. Trimethoprim-sulfamethoxazole-induced vanishing bile duct syndrome. Am J Gastroenterol 1997; 92: 167-9.
86. Kowdley KV, Keeffe EB, Fawaz KA. Prolonged cholestasis due to trimethoprim sulfamethoxazole. Gastroenterology 1992; 102: 2148-50.
87. Fries J, Siragenian R. Sulfonamide hepatitis. Report of a case due to sulfamethoxazole and sulfisoxazole. N Engl J Med 1966; 274: 95-7.
88. Ogilvie AL, Toghill PJ. Cholestatic jaundice due to co-trimoxazole. Postgrad Med J 1980; 56: 202-4.
89. Steinbrecher UP, Mishkin S. Sulfamethoxazole-induced hepatic injury. Dig Dis Sci 1981; 26: 756-9.
90. Boardman RH. Fatal case of toxic hepatitis implicating chlorpromazine. Br Med J 1954; 2: 579.
91. Moradpour D, Altorfer J, Flury R, et al. Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis. Hepatology 1994; 20: 1437-41.
92. Melrose AG, Roy JR. Late prognosis of chlorpromazine jaundice. Br Med J 1959; 1: 818-19.
93. Walker CO, Combes B. Biliary cirrhosis induced by chlorpromazine. Gastroenterology 1966; 51: 631-40.
94. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002; 22: 145-55.
95. Sabate M, Ibanez L, Perez E, et al. Risk of acute liver injury associated with the use of drugs: a multicentre population survey. Aliment Pharmacol Ther 2007; 25: 1401-9.
96. Read AE, Harrison CV, Sherlovk S. Chronic chlorpromazine jaundice: with particular reference to its relationship to primary biliary cirrhosis. Am J Med 1961; 31: 249-58.
97. Lok AS, Ng IO. Prochlorperazine-induced chronic cholestasis. J Hepatol 1988; 6: 369-73.
98. Waitzkin L. Prolonged hepatic dysfunction after clinical recovery from chlorpromazine jaundice. Gastroenterology 1962; 43: 337-9.
99. Regal RE, Billi JE, Glazer HM. Phenothiazine-induced cholestatic jaundice. Clin Pharm 1987; 6: 787-94.
100. Bolton BH. Prolonged chlorpromazine jaundice. Am J Gastroenterol 1967; 48: 497-503.
101. Abdel-Rahman SM, Nahata MC. Oral terbinafine: a new antifungal agent. Ann Pharmacother 1997; 31: 445-56.
102. Garcia Rodriguez LA, Duque A, Castellsague J, Perez-Gutthann S, Stricker BH. A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol 1999; 48: 847-52.
103. Severe liver damage on terbinafine. Prescrire Int 2002; 11: 16.
104. Fernandes NF, Geller SA, Fong TL. Terbinafine hepatotoxicity: case report and review of the literature. Am J Gastroenterol 1998; 93: 459-60.
105. Mallat A, Zafrani ES, Metreau JM, Dhumeaux D. Terbinafine-induced prolonged cholestasis with reduction of interlobular bile ducts. Dig Dis Sci 1997; 42: 1486-8.
106. Vivas S, Rodriguez M, Palacio MA, et al. Acute hepatitis associated with terbinafine. Gastroenterol Hepatol 1997; 20: 456-8.
107. Anania FA, Rabin L. Terbinafine hepatotoxicity resulting in chronic biliary ductopenia and portal fibrosis. Am J Med 2002; 112: 741-2.
108. Perveze Z, Johnson MW, Rubin RA, et al. Terbinafine-induced hepatic failure requiring liver transplantation. Liver Transpl 2007; 13: 162-4.
109. Gendre G, Buclin T, Morard I, Fontannaz J, Berney JL. Terbinafine induced hepatitis with persistent cholestasis. Revue medicale suisse 2008; 4: 736-9.
110. Tejada Garcia M, Llvona Hevia AM, Martin Arias L, Garcia-Pando AC. Terbinafine and cholestatic hepatitis. Med Clin 1997; 109: 356.
111. Gupta AK, Del Rosso JQ, Lynde CW, Brown GH, Shear NH. Hepatitis associated with terbinafine therapy: three case reports and a review of the literature. Clin Exp Dermatol 1998; 23: 64-7.
112. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-5.
113. Fromenty B, Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther 1995; 67: 101-54.
114. Labbe G, Pessayre D, Fromenty B. Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam Clin Pharmacol 2008; 22: 335-53.
115. Begriche K, Massart J, Robin MA, Borgne-Sanchez A, Fromenty B. Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J Hepatol 2011; 54: 773-94.
116. Kneeman JM, Misdraji J, Corey KE. Secondary causes of nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2012; 5: 199-207.
117. Fromenty B, Fisch C, Labbe G, et al. Amiodarone inhibits the mitochondrial beta-oxidation of fatty acids and produces microvesicular steatosis of the liver in mice. J Pharmacol Exp Ther 1990; 255: 1371-6.
118. Fromenty B, Fisch C, Berson A, et al. Dual effect of amiodarone on mitochondrial respiration. Initial protonophoric uncoupling effect followed by inhibition of the respiratory chain at the levels of complex I and complex II. J Pharmacol Exp Ther 1990; 255: 1377-84.
119. Ramachandran R, Kakar S. Histological patterns in drug-induced liver disease. J Clin Pathol 2009; 62: 481-92.
120. Nguyen MC, Stewart RB, Banerji MA, Gordon DH, Kral JG. Relationships between tamoxifen use, liver fat and body fat distribution in women with breast cancer. Int J Obes Relat Metab Disord 2001; 25: 296-8.
121. Ghabril M, Vuppalanchi R. Drug-induced nodular regenerative hyperplasia. Semin Liver Dis 2014; 34: 240-5.
122. Steiner PE. Nodular regenerative hyperplasia of the liver. Am J Pathol 1959; 35: 943-53.
123. Dachman AH, Ros PR, Goodman ZD, Olmsted WW, Ishak KG. Nodular regenerative hyperplasia of the liver: clinical and radiologic observations. AJR Am J Roentgenol 1987; 148: 717-22.
124. Rothweiler S, Terracciano L, Tornillo L, et al. Downregulation of the endothelial genes Notch1 and ephrinB2 in patients with nodular regenerative hyperplasia. Liver Int 2014; 34: 594-603.
125. Mallet V, Blanchard P, Verkarre V, et al. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS 2007; 21: 187-92.
126. Daniel F, Cadranel JF, Seksik P, et al. Azathioprine induced nodular regenerative hyperplasia in IBD patients. Gastroenterol Clin Biol 2005; 29: 600-3.
127. Buffet C, Cantarovitch M, Pelletier G, et al. Three cases of nodular regenerative hyperplasia of the liver following renal transplantation. Nephrol Dial Transplant 1988; 3: 327-30.
128. Hartleb M, Gutkowski K, Milkiewicz P. Nodular regenerative hyperplasia: evolving concepts on underdiagnosed cause of portal hypertension. World J Gastroenterol 2011; 17: 1400-9.
129. Shepherd PC, Fooks J, Gray R, Allan NC. Thioguanine used in maintenance therapy of chronic myeloid leukaemia causes non-cirrhotic portal hypertension. Results from MRC CML. II. Trial comparing busulphan with busulphan and thioguanine. Br J Haematol 1991; 79: 185-92.
130. Shepherd P, Harrison DJ. Idiopathic portal hypertension associated with cytotoxic drugs. J Clin Pathol 1990; 43: 206-10.
131. Ranucci G, Cirillo F, Della Corte C, et al. Successful use of ursodeoxycholic acid in nodular regenerative hyperplasia of the liver. Ann Pharmacother 2011; 45: e20.
132. Bihl F, Janssens F, Boehlen F, et al. Anticoagulant therapy for nodular regenerative hyperplasia in a HIV-infected patient. BMC Gastroenterol 2010; 10: 6.
133. Tsokos M, Erbersdobler A. Pathology of peliosis. Forensic Sci Int 2005; 149: 25-33.
134. Nieves Cereceda C, Solis Herruzo JA, Munoz-Yague MT, De Blas C. Hepatic peliosis. Review of the literature. Rev Esp Enferm Apar Dig 1989; 75: 205-11.
135. Loomus GN, Aneja P, Bota RA. A case of peliosis hepatis in association with tamoxifen therapy. Am J Clin Pathol 1983; 80: 881-3.
136. Engelberg M. Diagnosis and treatment of malignant liver tumors. Harefuah 1977; 93: 416-18.
137. Thung SN, Gerber MA. Precursor stage of hepatocellular neoplasm following long exposure to orally administered contraceptives. Hum Pathol 1981; 12: 472-4.
138. Eugene M, Chong MF, Genin R, Amat D. [Peliosis hepatis and oral contraceptives: a case report]. Mediterr Med 1985; 13: 21-4.
139. Editorial: liver tumours and steroid hormones. Lancet 1973; 2: 1481.
140. Bagheri SA, Boyer JL. Peliosis hepatis associated with androgenic-anabolic steroid therapy. A severe form of hepatic injury. Ann Intern Med 1974; 81: 610-18.
141. Spormann H, Willgeroth C, Tautenhahn P. Peliosis hepatis with liver rupture. Zentralbl Allg Pathol 1985; 130: 545-50.
142. Adam G, Lesser T, Neumann R. Liver rupture in peliosis hepatis. Zentralbl Chir 1991; 116: 399-403.
143. Gisbert PJ, Gonzalez A, Moreira V, et al. An intrahepatic hematoma secondary to peliosis hepatis in a female patient treated with oral contraceptives. Rev Esp Enferm Dig 1994; 85: 475-7.
144. Van Erpecum KJ, Janssens AR, Kreuning J, et al. Generalized peliosis hepatis and cirrhosis after long-term use of oral contraceptives. Am J Gastroenterol 1988; 83: 572-5.
145. Aires CC, Ijlst L, Stet F, et al. Inhibition of hepatic carnitine palmitoyl-transferase I (CPT IA) by valproyl-CoA as a possible mechanism of valproate-induced steatosis. Biochem Pharmacol 2010; 79: 792-9.
146. Maor Y, Malnick S. Liver injury induced by anticancer chemotherapy and radiation therapy. Int J Hepatol 2013; 2013: 815105.